IMPORTANCE Individually designed single-patient multi-crossover (n-of-1) trials can facilitate tailoring of treatments directed at various conditions, including chronic musculoskeletal pain (CMSP) but are potentially burdensome, which may limit uptake in research and practice.
I ndividually designed single-patient multi-crossover (nof-1) trials are experiments in which patients switch between 2 or more treatments. 1 In contrast with parallelgroup randomized clinical trials, which estimate average treatment effects in the population studied, the n-of-1 crossover design permits estimation of treatment effects for each individual participant. 2, 3 Additionally, n-of-1 trials are most appropriate for chronic stable diseases and for treatments with rapid onset and minimal carryover following treatment switching. 4 Although used in diverse conditions, [5] [6] [7] [8] [9] [10] [11] [12] n-of-1 trials have not been widely adopted, in part because they have been perceived by clinicians and patients as requiring too much time and effort. 13 Patients with chronic musculoskeletal pain (CMSP) are at high risk of physical disability, emotional distress, and work absenteeism. [14] [15] [16] Analgesic medications are the traditional mainstay of CMSP treatment, but opioid-related concerns 17 have prompted clinicians to consider alternatives. 18, 19 We hypothesized that participation in an n-of-1 trial might benefit patients with CMSP, either by steering patients toward more personally effective therapies or by expanding patient involvement in care. 20 To assess the impact of n-of-1 trials as a decision-making and patient-engagement strategy in chronic pain, we conducted a randomized clinical trial, assigning patients with CMSP to participate in individually designed n-of-1 trials or to receive usual care. We hypothesized that n-of-1 trial participants would report improved outcomes. 21 We also sought to determine whether use of a mobile health (mHealth) app would address barriers to n-of-1 trial participation and would be evaluated positively by patients.
Methods

Overview
As described elsewhere, 22 the Personalized Research for Monitoring Pain Treatment study compared assignment to an mHealth-supported n-of-1 trial vs usual care in diverse primary care settings. The study sought to assess the possible benefits of participating in an n-of-1 trial, not to assess the superiority or inferiority of any particular treatment. Enrollment began in July 2014 and, in an effort to achieve the target sample of 244 patients, was extended from January 2016 to July 2016. Follow-up ended in May 2017. The primary study outcome was pain-related interference 6 months after study entry (full scale range, 41-78).
Setting and Participants
The study was conducted in northern California with recruitment at the University of California, Davis (UC Davis) Primary Care Network; UC Davis Family Medicine Clinic; UC Davis General Medicine Clinic; Veterans Affairs Northern California Health Care System; and David Grant Medical Center at Travis Air Force Base. Institutional review board approval, as well as written informed consent from all patients, was obtained at each site. The trial protocol for this study is available in Supplement 1.
Participating clinicians included 21 general internists, 21 family physicians, 2 Veterans Affairs pain specialty physicians practicing in close association with primary care, 1 nurse practitioner, 2 physician assistants, and 1 clinical pharmacist. Of the participating clinicians, 60% (n = 29) were recruited from UC Davis, the mean (SD) age was 44 (10) years; the mean (SD) time in practice was 12.5 (9.5) years, and 50% (n = 24) were female. Clinicians received a small participation incentive (ie, $100 gift card for each patient completing the 6-month follow-up). The median number of study patients per clinician was 3.
Every 6 months, information services personnel at participating sites generated a list of patients with an International Classification of Diseases, Ninth Revision musculoskeletal pain diagnosis who were under the care of an enrolled clinician. These patients (n = 10 867) were sent a letter describing the study and inviting them to contact research staff. Interested patients were screened by telephone, and Englishspeaking adults (18-75 years old) were potentially eligible if they had musculoskeletal pain for at least 6 weeks at the time of screening, had a smartphone or tablet (Android or iOS) with a data plan, and reported a score of 4 or higher out of 10 on at least 1 item of the 3-item pain, enjoyment, and general activity questionnaire.
Intervention
After administering baseline questionnaires, the research assistant accompanied the patient into the examination room to facilitate n-of-1 trial setup via a desktop interface. Based on the clinician's judgment and the patient's preferences, the clinicianpatient dyad selected from 8 treatment categories: (1) acetaminophen; (2) any nonsteroidal anti-inflammatory drug; (3) acetaminophen/codeine; (4) acetaminophen/hydrocodone; (5) acetaminophen/oxycodone; (6) tramadol; (7) complementary/ alternative treatments such as massage, meditation, or physical exercise; or (8) current ongoing therapy (or no therapy). Shortacting opioids were included as options because they are in common use in primary care and because it was believed that some patients might benefit from eliminating them. 25 Treatment regimens for comparison (eg, treatment A and treatment B) could be single agents (eg, acetaminophen) or combinations (eg, acetaminophen plus tramadol). Trials could be structured to compare treatments between categories (eg, acetaminophen vs acupuncture) or treatments within category (eg, massage vs yoga). Dyads also chose the duration of each treatment period (1 or 2 weeks), the number of paired comparisons (2, 3, or 4) , and the start date. Trials could last 4, 6, 8, or 12 weeks.
Trial parameters were sent to the Trialist system (an opensource mobile app supported by a server-based back end developed by OpenmHealth.org) on the patient's mobile device. The system randomly chose a balanced treatment sequence (eg, ABAB); alerted the patient when to begin each treatment; and sent a daily questionnaire covering pain on average, pain interference with enjoyment of life, and pain interference with daily activities (each self-assessed over the past 24 hours), as well as 5 potential adverse effects of treatment (drowsiness, fatigue, constipation, sleep problems, and cognitive impairment). To improve study adherence, study staff contacted patients by telephone or email for failing to start a trial as scheduled or for not completing at least 4 daily questionnaires per week (out of 7 expected).
At trial completion, patients were asked to meet with their clinician for a results review visit to discuss the n-of-1 trial experience while addressing any new or ongoing clinical concerns. Each dyad was provided graphs depicting their n-of-1 trial results, which were generated by comparing outcomes between regimens (treatment A vs treatment B), first descriptively ( Figure 1A and B) and then using Bayesian models yielding absolute differences with 95% credible intervals ( Figure 1C ) and probabilities of small, medium, and large effects. To aid in interpretation, physicians had access to online instructional videos. Patients unable to schedule a results review visit within 8 weeks of n-of-1 trial completion could review results by telephone or email.
Control Condition
Patients assigned to the control group attended a baseline clinic visit where they completed assessments in the waiting room under the supervision of the study research assistant. Otherwise they received care as usual.
Outcomes and Follow-up
All study patients were expected to complete outcome assessments at baseline and at approximately 3, 6, and 12 months. The primary prespecified outcome was change in the PatientReported Outcomes Measurement Information System (PROMIS) pain-related interference 8-item short-form scale (full scale range, 41-78) from baseline to 6 months. 26, 27 We focused on the 6-month interval to allow time for patients to complete their n-of-1 trial, complete a results review visit, settle into a new therapeutic regimen based on trial results, and apply skills learned during the n-of-1 experience (eg, being aware of exacerbating and alleviating factors). We assessed this outcome as the mean difference between intervention and control groups.
In an analysis that was not prespecified, we also assessed the difference in the proportion of patients achieving a 5-point improvement in PROMIS pain-related interference. A 5-point improvement represented a statistically significant change at the individual level given the measured reliability (0.95) and SD (5.8) in our sample. 28, 29 Secondary outcomes included pain interference at 3 and 12 months, 30 as well as the following outcomes measured at 3, 6, and 12 months: pain intensity using the PROMIS 3a short form 30 ; physical and mental global health using the 10-item PROMIS Global Health scale, version 1. 34 Among patients who reported talking with the clinician "who prescribes your pain treatments" about "starting or stopping a prescription medication…in the last 12 months," we also assessed medication-related shared decision making using a 3-item scale from the Consumer Assessment of Healthcare Providers and Systems survey at 6 and 12 months.
35,36
Patients' n-of-1 Experiences
To characterize experiences of patients using the Trialist app, we asked intervention group patients to rate the helpfulness of the Trialist app along 5 dimensions, from 1 (extremely helpful) to 5 (not at all helpful). In addition, patients were asked "Do you believe the Trialist app could help people like you manage their pain (yes or no)?" We also asked patients to rate 10 statements from the System Usability Scale, 37 from 1 (strongly agree) to 5
(strongly disagree). See Table 1 for specific wording.
Statistical Analysis and Power
The primary analysis comparing n-of-1 vs usual care followed the intention-to-treat principle, accounting for all participants as randomized. The planned sample size of 244 was calculated based on the assumption of a minimally important difference of 0.4 SDs on the PROMIS pain-related interference scale. 29 Assuming a 10% dropout rate, 122 patients in each group would provide 80% power to detect a 0.36-SD (3.6-point) difference in mean T scores (general population mean, 50; SD, 10) using a 2-group t test with 2-sided alpha equaling 0.05. Outcomes were analyzed with longitudinal mixed effects Gaussian models combining baseline, 3-, 6-, and 12-month measurements using time, treatment, and a time-bytreatment interaction as fixed effects, and clinician and patient as random effects. Such models account properly for missing outcomes when the probability of missingness depends on the values of previous outcomes. 38 Because Consumer Assessment of Healthcare Providers and Systems survey questions assessing medication-related shared decision making were applicable only to patients who had talked with their clinicians about starting or stopping treatment with a medication in the past 12 months, this outcome was assessed by comparing mean scale scores (with 95% CIs) for intervention and control patients at 6 and 12 months. We also conducted exploratory analyses examining interactions between the intervention and covariates including age, sex, race, ethnicity, marital status, education, employment status, study site, baseline opioid use, and CMSP pain category (eg, axial [ie, neck/back], extremity, other). All model assumptions were checked with standard regression diagnostics. Patients missing the primary outcome at 3, 6, and 12 months were similar demographically to those not missing the primary outcome, but they were less likely to be taking opioids at baseline and had slightly worse baseline health (eTable in Supplement 2). In regressions that adjusted for missingness, results were not substantially different than in the base case. All analyses were performed using R software, version 3.3.1 (R Foundation). Patients and clinicians were provided with 6 graphs during the results review visit; 3 are depicted here. The graphs were intended to be devoid of jargon and easily understood and interpreted by patients and clinicians. Clinicians were provided access to brief web-based training videos to assist them in interpreting the graphs for their patients. The patient in this example compared acetaminophen as treatment A (shown in light blue) with a nonsteroidal anti-inflammatory drug as treatment B (shown in dark blue). The graphs in panels B and C depict 6 patient-centered outcomes (pain intensity, fatigue, drowsiness, sleep problems, thinking problems, and constipation) comparing treatment A with treatment B. A, The daily ratings on a 0-to 10-point scale for pain intensity, which were entered into the Trialist app by the patient. Zero indicates no pain, and 10 the highest level of pain. Each data point indicates 1 day. B, The average of daily ratings on a 0-10 scale for each outcome. Zero designates the best outcome. C, The outcomes are shown as squares representing point estimates for relative improvement, with lines representing the 95% credible intervals, and color shading and labeling to facilitate decision making. The analysis in this panel was based on a Bayesian model that estimated the posterior distribution of the difference between symptom scores comparing treatment A with treatment B. 
Results
Of 1092 patients assessed for eligibility, 732 did not meet inclusion criteria, and 145 were eligible but not randomized ( Figure 2) . The remaining 215 patients were randomized, 108 to the intervention group and 107 to control, including 22 who were enrolled too late for follow-up past the 6-month mark and were therefore missing 12-month (secondary) outcomes. Among participants, mean (SD) age was 55.5 (11.1) years, 47% (n = 102) were women, 26% (n = 56) were nonwhite, 55% (n = 119) lacked a college degree, 52% (n = 112) were not currently working, and 45% (n = 86) were on opioids at baseline ( Patients who no longer wished to continue in the study were classified as withdrew. Patients who could not be located were classified as lost to follow-up, while those missing data at a particular follow-up time point were classified as did not complete follow-up. Patients who had not completed the intervention before the 3-month window ended were classified as completed the results review visit after the follow-up window had closed. Patients enrolled at the end of the recruitment period and not followed beyond 6 months were classified as enrolled within 12 months of end of study. a Percentages represent the proportion of affirmative responses, defined as "extremely or very helpful" and as "strongly agree" or "agree," among patients completing an n-of-1 trial and who responded to the specific survey question. Item nonresponse ranged from 0 to 5 patients.
cal therapy, tai chi, massage, acupuncture, mindfulness meditation). Results review visits were completed in person (n = 80), by mail (n = 13), or through an electronic patient portal (n = 2). Among patients finishing their n-of-1 trial, the median daily questionnaires completed was 71% (n = 95).
Primary Outcome
In the intention-to-treat analysis of the 6-month PROMIS paininterference scale, patients in the intervention group improved slightly more than those in the control group, but there was no significant difference in change from baseline between the intervention and control groups (−1.36 points; 95% CI, −2.91 to 0.19 points; P = .09) ( Table 3) . Intervention patients were more likely than controls to register an improvement of 5 or more points in PROMIS pain interference at 6 months (34% [n = 37] vs 22% [n = 23]; P = .05). Table 3 and the eFigure in Supplement 2 detail outcomes for the intervention and control groups at 3, 6, and 12 months. For most outcomes, patients assigned to the n-of-1 group improved more or declined less than controls, but there were no statistically significant differences between the groups. At the 6-month follow-up, more patients in the intervention group than control group reported that they had discussed starting or stopping treatment with a medication with the clinician who prescribed their pain treatments (57% [n = 62] vs 42% [n = 45]; P = .02). Among those so-reporting (n = 107), medication-related shared decision-making scores were higher among intervention patients than control patients (mean scale score, 79.6 vs 67.6; difference, 11.9; 95% CI, 2.6-21.2; P = .01). Results at 12 months were similar but not significant (74.8 vs 65.4; difference, 9.4; 95% CI, −0.15 to 19.0; P = .05).
Secondary Outcomes
Patients' n-of-1 Trial Experiences
Among patients initiating an n-of-1 trial, 88% (n = 86) reported that they believed the Trialist app could help people like them manage their pain and 81% (n = 77) found it "extremely or very helpful" in keeping track of their pain (Table 1) . (13) 12 (11) 15 (15) Asian 12 (6) 8 (7) 4 (4) Other 17 (8) 13 (12) 4 (4) Latino, No. (%) 24 (11) 16 (15) 8 ( (5) 5 (5) 5 (5) Divorced or separated 43 (20) 21 (19) 22 (21) Never married 16 (8) 7 (7) 9 (9) Education, No. (%)
High school diploma or less 16 (7) 6 (6) 10 (9) Some college and/or associate degree and/or vocational training 103 (48) 54 (50) 49 (46) Bachelor's degree 56 (26) 23 (21) 33 (31) Master's or doctoral or professional degree 40 (19) 25 (23) 15 (14) Employment, No. (%)
Full time (≥35 h/wk) 85 (40) 40 (37) 45 (42) Part time (<35 h/wk) 18 (8) 12 (11) Smaller majorities rated the app as helpful in working closely with their clinician, noticing things that made pain feel better, and having more confidence in the patient management approach going forward, while 49% (n = 46) found the app helpful in identifying pain triggers ( Table 1) . Results of the System Usability Scale suggested that the app was generally viewed as being easy to use (Table 1) .
Sensitivity Analyses and Heterogeneity of Treatment Effects
Two sensitivity analyses were conducted. In the first, we performed a modified "as treated" analysis, reclassifying as controls the 10 patients assigned to the intervention group but who did not begin their n-of-1 trials. In the second, under the assumption that return of daily surveys would be correlated with adherence to the n-of-1 protocol, we assigned each patient in the intervention group a value between 0 and 100 to represent the percentage of daily outcome measurements they reported; control patients took on the value 0. Results of both sensitivity analyses were not materially different from those of the main analysis and are therefore not reported further. In addition, there were no more treatment-by-time-bycovariate interaction effects (P < .05) than would be expected by chance.
Safety
No trial-related adverse events were reported.
Discussion
This study addressed whether patients with CMSP who were randomized to an n-of-1 trial program would achieve better health outcomes and report better care experiences than those assigned to usual care. While patients in both groups improved from baseline with respect to the primary outcome of pain interference, there was no difference between the groups. In this study, the primary outcome failed. 39 However, 3 additional observations are pertinent. First, most findings favored n-of-1 participation. Second, more patients in the nof-1 group than in the usual-care group achieved a 5-point improvement in pain interference, which represents a statistically significant change at the individual level. 28 Third, medi- a In contrast to other measures, which were obtained at the baseline visit, PEG scores were obtained at screening. Mean scores were clinically comparable and statistically nonsignificant (P = .31).
b Baseline opioid use was assessed via medical record review among patients who provided permission for such review (n = 190 total; 97 in the intervention group and 93 in control).
c All scales had a theoretical range of 0 to 100 except for PEG (range, 0-10); in all cases 0 was the best possible score. Higher scores indicate better physical health.
h Mean differences between n-of-1 and control groups, P < .05.
i PROMIS global mental health scores in this sample ranged from 21.3 to 63.6. Higher scores indicate better mental health.
j Scores in this sample ranged from 37.5 to 100. Higher scores indicate greater adherence and less overuse of medication.
k Scores in this sample ranged from 0 to 100. Higher scores indicate greater adherence and less underuse of medication.
l Scores in this sample ranged from 20.5 to 100. Higher scores indicate greater trust.
m Scores in this sample ranged from 0 to 100. Higher scores indicate greater satisfaction.
n Scores in this sample ranged from 15 to 100. Higher scores indicate greater satisfaction.
o Scores in this sample ranged from 0 to 100. Higher scores indicate greater satisfaction.
p Medication-related shared decision-making scores, which were computed only for patients who reported discussing medications with their clinician in the past 12 mo, ranged from 0 to 100 in this sample. Higher scores indicate more shared decision making.
cation-related shared decision making was better in the intervention group. There were more discussions about medication as well as higher-quality discussions. Enhanced patient engagement in care has been touted as a benefit of n-of-1 trials and may mediate effects on health. 40 While none of these observations are by themselves practice changing, they do underscore the need for more research.
This study also adds important information about whether relatively unselected patients with chronic pain are willing to participate in and persist with n-of-1 trials. Most n-of-1 participants were diligent about providing daily symptom reports; patients found the mobile device app easy to use, and most patients found it helped them better manage their pain. Just 23% (n = 22) of completed n-of-1 trials statistically favored 1 treatment regimen over the other. However, even null n-of-1 trials could deliver useful information for decision making. While highlighting many challenges, our experience shows that n-of-1 trials are a potentially appealing vehicle for delivering precision medicine in office practice. 41 
Limitations
This evaluation incorporated a large n-of-1 series by historical standards, 5 was conducted in diverse practices, used a strong randomized design, and emphasized patient-centered outcomes but was not without limitations. Patients were aware of the arm to which they were randomized; intervention patients received more attention than controls, and patients in the n-of-1 arm were aware of the pain-treatment regimens being compared. In the context of n-of-1 trials, lack of blinding is not always a limitation, depending on what one considers the active therapeutic ingredient. On the other hand, nearly all clinicians had patients in both arms, raising the prospect that clinicians might alter their communication style or medical decisions with 1 group based on experience with the other, biasing estimates toward the null. The study population was clinically heterogeneous. The number of study sites was limited, and all were from a single region. Although we received no clinician or patient reports of study-associated adverse events, the relatively small sample size and passive monitoring strategy may have missed n-of-1 trial-associated harms. Slow recruitment led to a 12% shortfall in anticipated enrollment and a 12-month (secondary) outcome missingness rate of 10%. Finally, even with mHealth support, n-of-1 trials place nontrivial demands on clinical practice, which may limit their uptake to enthusiasts.
Conclusions
In summary, clinicians and patients were willing to undertake mHealth-supported n-of-1 trials, but participation did not significantly improve the primary outcome of pain interference at 6 months. Nevertheless, n-of-1 trials may appeal toand have value for-selected patients willing to join in clinicianguided self-experimentation. Additional research is needed to clarify which patients are most likely to benefit from participation in mHealth-supported n-of-1 trials and under what circumstances. Role of the Funder/Sponsor: The funders had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 
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The PREEMPT study -evaluating smartphoneassisted n-of-1 trials in patients with chronic pain: study protocol for a randomized controlled trial 
Abstract
Background: Chronic pain is prevalent, costly, and clinically vexatious. Clinicians typically use a trial-and-error approach to treatment selection. Repeated crossover trials in a single patient (n-of-1 trials) may provide greater therapeutic precision. N-of-1 trials are the most direct way to estimate individual treatment effects and are useful in comparing the effectiveness and toxicity of different analgesic regimens. The goal of the PREEMPT study is to test the 'Trialist' mobile health smartphone app, which has been developed to make n-of-1 trials easier to accomplish, and to provide patients and clinicians with tools for individualizing treatments for chronic pain.
Methods/design: A randomized controlled trial is being conducted to test the feasibility and effectiveness of the Trialist app. A total of 244 participants will be randomized to either the Trialist app intervention group (122 patients) or a usual care control group (122 patients). Patients assigned to the Trialist app will work with their clinicians to set up an n-of-1 trial comparing two pain regimens, selected from a menu of flexible options. The Trialist app provides treatment reminders and collects data entered daily by the patient on pain levels and treatment side effects. Upon completion of the n-of-1 trial, patients review results with their clinicians and develop a long-term treatment plan. The primary study outcome (comparing Trialist to usual care patients) is pain-related interference with daily functioning at 26 weeks.
Discussion: Trialist will allow patients and clinicians to conduct personalized n-of-1 trials. In prior studies, n-of-1 trials have been shown to encourage greater patient involvement with care, which has in turn been associated with better health outcomes. mHealth technology implemented using smartphones may offer an efficient means of facilitating n-of-1 trials so that more patients can benefit from this approach.
Trial registration: ClinicalTrials.gov: NCT02116621, first registered 15 April 2014.
Keywords: N-of-1, Chronic pain, eHealth, mHealth, Smartphone, Randomized controlled trial
Background
Chronic pain is highly prevalent [1] costly [2] , and clinically vexatious [3] . Twenty percent of primary care patients are estimated to have persistent pain [4] . Patients experiencing persistent or chronic pain are more likely to have an anxiety or depressive disorder; they also are more likely to have limitations in physical functioning than patients without pain [4, 5] . Pain is estimated to cost the United States (US) economy $560 to 630 billion annually due to health care expenditures and lost productivity [2] . Musculoskeletal pain is the most common reason for work disability and work absence [6] . Drug therapy is a mainstay of chronic pain management in primary care. Current drug treatment strategies for chronic painful conditions convey a mix of benefits and hazards. In usual practice, clinicians often begin with acetaminophen or a non-steroidal anti-inflammatory drug (NSAID), prescribing opioids when pain is severe or unresponsive [7, 8] . When the analgesic response to the initial treatment is inadequate, clinicians can invoke stepped care, dose titration, opioid rotation, or augmentation with adjuvants such as anti-convulsants [8] [9] [10] . These approaches are usually employed in a non-systematic, trialand-error fashion [11] , which can appear to work in the short run but may lead to poor therapeutic decisions in the long run. A treatment that appears effective over a short period may only seem so because of random fluctuation in the patient's underlying condition, uncontrollable external factors, placebo effect, or regression to the mean [7, 12] .
N-of-1 trials are single-subject crossover experiments [13] in which a patient completes repeated treatments comparing two treatment regimens. Also called singlepatient trials [14] , single-subject trials [15] , single-case experiments [16] , and individual-patient trials [14] , n-of-1 trials switch patients back and forth between two treatments several times. Clinicians can then identify the more effective approach for an individual patient [12] . N-of-1 trials are appropriate for chronic, stable conditions and for treatments that have a rapid onset [14] and short half-life [15] . They are particularly suitable when available therapies are thought to have substantial heterogeneity of treatment effects (HTE), implying significant variation across patients as to which treatment works best. When HTE is large, average effects may mislead, calling for a more personalized approach [17] .
N -o f -1t r i a l sa r et h em o s td i r e c tw a yt oe s t i m a t ei n d ividual treatment effects [14] . However, n-of-1 trials have not yet gained traction with clinicians, patients, and the scientific community. A major barrier is the perception that such trials demand too much time and effort [18] . The use of mobile health (mHealth) technologies to enhance care access and delivery [19] is a promising approach to reduce perceived barriers to nof-1 participation. Smartphones are increasingly used in care innovation research [20] and provide an opportunity to develop interventions at lower cost and with decreased provider burden [21] than was possible before the integration of mobile technologies into daily life. Smartphones have been used to improve pain and health outcomes through the use of specialized software applications (apps) for assessing symptoms, facilitating communication between patients and providers, tracking outcomes [22] , delivering information [23] and tracking behaviors. In pain settings, apps have been developed to record diary entries [24] [25] [26] and allow therapists to send tailored text messages to patients [26] . In non-pain settings, smartphones have been used in randomized controlled trials (RCTs) to track physical activity [27] , monitor weight loss [21] , and improve nutrition [28] . More than 125 million people in the US own smartphones, 50 million people own tablets [29] , and smartphones account for more than 50% of mobile phone sales. Android (for example, Google Nexus series (Google, Mountain View, CA, USA), Samsung Galaxy series (Samsung, San Jose, CA, USA)) and iOS (for example, iPhone, iPad, iPod Touch (Apple Inc., Cupertino, CA, USA)) devices account for over 90% of the smartphone market [29] .
N-of-1 trials have the potential to expand patient involvement and promote more personalized, patientcentered health care. From the population perspective, if mHealth-based n-of-1 trials can help patients and clinicians achieve therapeutic success faster and with greater confidence, patients may require fewer subsequent office visits, tests, emergency room visits, and after-hours telephone support, thus lessening the burden on health systems and saving money.
The goal of the PREEMPT (Personalized REsEarch for Monitoring Pain Treatment) study is to make n-of-1 trials easier to accomplish, to provide patients and clinicians with tools for individualizing treatments for chronic pain, and to evaluate this approach in terms of patient outcomes. A smartphone app called the 'Trialist' has been developed in collaboration with Open mHealth, a non-profit mobile health developer. The feasibility and efficacy of the 'Trialist' smartphone app is being assessed in a RCT to compare the effects of participating in a mobile n-of-1 trial versus usual care on patient outcomes including pain-related interference with daily functioning, pain intensity, participatory decision-making, medication adherence, and general health-related quality of life. Achieving these aims will set the stage for broader uptake of mHealth n-of-1 trials in chronic pain as well as other chronic health conditions.
Methods/design
PREEMPT is a RCT with a planned total of 244 participants randomized to the Trialist app intervention or a usual care control group.
Study setting
The study is located in Northern California with recruitment occurring within the University of California, Davis (UC Davis) Primary Care Network, UC Davis Family Medicine Clinic, UC Davis General Internal Medicine Clinic, and the Veterans Affairs Northern California Health Care System (VANCHS). These networks are located within the greater metropolitan areas of Sacramento and Yolo counties.
Study hypothesis
The primary study hypothesis is that, compared to usual care, patients randomized to the Trialist will experience less pain interference (impairment of daily functioning including work outside the home, housework, and social activities) at 26 weeks follow-up. Secondary hypotheses are: compared to usual care, patients randomized to the Trialist will experience less pain interference, less pain intensity, better general health-related quality of life, improved participatory decision-making, greater satisfaction with pain treatment, better adherence to prescribed therapy, and a better patient experience with care, each measured as longitudinal change from baseline up to 52-weeks follow-up.
Eligibility criteria
Study participants include patients as well as their regular treating clinicians. Clinicians are recruited first, and must have completed residencies in internal medicine, family medicine, or pain medicine or be practicing nurse practitioners or physician assistants. Patients, recruited from the practices of consenting clinicians, are required to meet the following criteria: English speaking adults between 18 and 75 years old who have experienced ongoing musculoskeletal pain for 6 weeks or longer; own an eligible iOS or Android smartphone or tablet; have a pain score of 4 or higher (on a 0 to 10 scale where 10 is the 'worst pain imaginable') on at least 1 of 3 items from the PEG pain scale [30, 31] ; and in the judgment of the treating clinician, have pain potentially amenable to treatment with acetaminophen, NSAIDs, low-dose opioids, tramadol, a complementary/alternative treatment such as massage or meditation, or a combination of these treatments (since these treatments are among those offered on the Trialist 'menu'). Patients are excluded if they are pregnant or breastfeeding; have undergone surgery, radiation or chemotherapy treatment for cancer in the past 5 years; or have other medical conditions or behaviors, such as bipolar disorder or current alcohol or prescription drug abuse, rendering them unsuitable for the trial. (See Table 1 for a complete list of patient inclusion and exclusion criteria.)
Recruitment
Clinicians are recruited via flyers, Emails, letters and presentations. Once clinicians indicate interest, informed consent is obtained detailing their responsibilities and soliciting their consent to have their patients recruited into the study. Clinicians receive a $100 gift card for each patient who is enrolled and guided through the study.
Two methods are used for patient recruitment. First, clinicians can ask patients directly if they are interested in the study. Clinicians provide interested patients with a study flyer that provides research staff contact information. Second, patients of enrolled clinicians who have been seen within the past 2 to 12 months for a chronic painful condition (as indicated by appropriate International Statistical Classification of Diseases and Related Health Problems (ICD-9) codes) are sent an informational letter informing them about the study and inviting them to contact research staff if interested in learning more. Both patient recruitment methods rely on patients initiating contact with PREEMPT study research staff. (See Figure 1 for the participant flow diagram and Additional file 1 for the ICD-9 codes.) For completing the study, patients receive a gift card worth $50 (control patients) or $100 (intervention patients).
Screening
Patients are screened for eligibility over the telephone. Research staff explain the study and ask initial screening questions to assess pain levels and determine that the patient has an eligible device. At this time, permission is obtained from the patient to contact his/her clinician for medical history screening. If permission is granted, the patient's clinician is contacted via secure Email and/or telephone to verify that the patient is an appropriate candidate for the study. Eligible patients are then recontacted by telephone or Email, notified of eligibility, and Patient has a medical condition/s that would limit the patient life expectancy to < 2 years or imperil patient safety A score of 4 or greater for at least one question of the PEG pain scale [31] Dementia, bipolar disorder, schizophrenia, or active suicidality
Based on clinician judgment the patient is amenable to treatment with acetaminophen, non-steroidal anti-inflammatory drugs, short-acting opioids, tramadol, a complementary/alternative treatment such as massage or meditation, or a combination of these treatments
Evidence of alcohol or prescription drug abuse, or have a history of disruptive behavior Ability to speak and read English Failed five or more analgesic medications because of lack of effectiveness or poor tolerance asked the date and time of their next clinic appointment. Once a patient is deemed eligible, a consent packet is mailed or Emailed with the study consent form and Health Insurance Portability and Accountability Act (HIPAA) authorization form. Informed consent will be obtained from all participants included in this study.
Randomization and allocation concealment
Patients are randomized to Trialist versus usual care. Randomization is stratified by clinician; each clinician's patients are randomized in blocks of size 4 (90% of blocks) or 6 (10% of blocks) in order to balance the numbers of participants per clinician and to minimize selection bias. Patients assigned to usual care will receive the usual course of care as prescribed by their clinician. The allocation sequence are generated by the study statisticians (CS and JS) and provided to the study coordinator (MM) in a format that allows for clinician block size to be masked until the study is completed and for patient randomization allocation to be masked until completion of the enrollment procedures.
Enrollment interview
The enrollment interview is conducted by research staff and occurs just prior to the patient'so u t p a t i e n t appointment in the clinic waiting room. If the signed consent form and HIPAA authorization form (allowing the research team access to the patient'sm e d i c a lr ecords) have not been received prior to the enrollment interview, these documents are obtained first for each patient. Then the patient's randomization assignment to either the Trialist app or usual care is revealed, and the patient completes a baseline questionnaire. At this visit, all patients receive a pain self-management booklet [32] .
Trialist intervention
Patients assigned to the intervention arm undergo a 'Treatment Planning Visit' with their clinician during a regularly scheduled appointment to design the patient's n-of-1 trial. Clinicians and patients use the desktop interface of the Trialist together to select two treatment regimens for comparison. The customized option allows patients and clinicians to select from among acetaminophen; any NSAID (for example, ibuprofen, naproxen); an opioid combination product containing codeine, hydrocodone or oxycodone; tramadol; or complementary/alternative treatments such as massage, meditation or physical exercise. The participating provider's clinical judgment and discussion with the patient determines which specific regimens to compare. Treatment regimens for comparison can be single agents (for example, acetaminophen) or combinations (for example, acetaminophen plus tramadol). Thus, the design of n-of-1 trials may range from simple (for example, acetaminophen versus low-dose hydrocodone/acetaminophen) to complex (low-dose acetaminophen/hydrocodone plus music therapy versus naproxen plus tramadol). If a clinician attempts to select combinations that are clinically inappropriate (for example, selecting two products both containing acetaminophen to be administered simultaneously), the Trialist will disallow that selection. The desktop interface also provides links to current prescribing standards and recommendations for the available drug treatment options. (See Additional file 2 for screenshots of the desktop interface.) Allowable n-of-1 trials will last a total of 4 to 12 weeks depending on the trial parameters selected. Trial parameters include the duration a patient is on each treatment before switching treatments (7 or 14 days), and the number of treatment pairs (cycles) they complete (2, 3, or 4) . At least two cycles (for example, ABAB, BABA, ABBA, or BAAB) are required for a valid n-of-1 trial. (See Table 2 for examples of possible trial configurations.) The clinician and patient jointly select a start date for the n-of-1 trial, allowing for time to fill prescriptions. The n-of-1 trial parameter bounds were selected to provide a compromise between greater precision (for example, increasing number of cycles), and practicality (that is trial lengths that maintain patient interest).
After an n-of-1 trial is set up, patients are provided login credentials for the Trialist smartphone app. The app is available free on Google Play and Apple'sA p pS t o r e . Research staff provide patients with information on how to use the Trialist app, including a help guide and an online video tutorial (available on the study website, http://www. ucdmc.ucdavis.edu/chpr/preempt/). Research staff also provide patients with ongoing technical support.
The Trialist app randomizes the treatment sequence and notifies the patients of the treatment they are scheduled to take, presents patients with a daily questionnaire tracking levels of pain and side effects of treatment such as fatigue and drowsiness, and provides daily reminders to complete the questionnaires. Most patients receive an 8-item daily questionnaire and 1 weekly question on adherence. Patients experiencing neuropathic pain can choose to specifically track 3 neuropathic symptoms (for a total of 11 daily items). Example daily questions include: 'What number best describes your pain on average during the past 24 hours?' on a 0 to 10 scale; 'I felt fatigued during the past 24 hours' on a 5-point scale from 'not at all' to 'very much'; and 'How often did you feel drowsy or sleepy today?' on a 6-point response scale from 'not at all' to 'very much'. The raw data are not included in the patient's medical record, and are not available to other applications outside of the Trialist infrastructure. Patients receive notifications on their device to change treatments after 7 or 14 days and to complete daily and weekly questionnaires, and they also receive motivational messages keying off their progress in the trial. Patients can also view a graph of their own data to date, which displays scores from the questionnaires in chronological order (see Figure 2 ). Adherence to the daily questionnaires is essential to ensure successful completion of a patient'sn -o f -1t r i a l . To improve adherence, patients are contacted by telephone and/or Email for: a) failure to start a trial by pressing the 'start button' in the Trialist app within 48 hours after a trial is due to start or b) completing fewer than 4 daily questionnaires in any week of the trial. All adherence-related support and contact with patients is recorded. See Figure 3 for screenshots of the Trialist app.
Upon completion of the n-of-1 trial, patients review trial results with their clinician during a 'Results Review Session'. This visit occurs during a regularly scheduled office appointment. Clinician and patients will be advised to schedule a primary care appointment within 4 weeks of completing an n-of-1 trial, allowing treatment decisions to occur shortly after a trial is completed. Clinicians access the patient's n-of-1 trial results using the Trialist desktop interface. The results are displayed in a series of graphs and text output. Six graphs will be displayed including raw data outputs and graphs showing 
Pain intensity
Pain intensity is assessed using the PROMIS adult scale v1.0 -Pain Intensity 3a. The scale includes 3 items on a 5-point response scale from 'no pain' to 'very severe'. Questions include: 'In the past 7 days, how intense was your pain at its worst?'' In the past 7 days, how intense was your average pain?' and 'What is your level of pain right now?'
Self-reported adherence
Self-reported adherence to pain treatment is assessed using the four-item Analgesic Adherence Scale developed to assess general medication adherence. The scale was developed by Rosser et al. [33] , who replicated the work of McCracken et al. [34] . The scale comprises 4 items on a 5-point response scale ('never' to 'always').
Questions include: 'How often do you take less medication (smaller doses) than prescribed?' and 'How often do you miss a dose of medication?'.
Participatory decision-making
Four items drawn from the Consumer Assessment of Healthcare Providers and Systems (CAHPS) PatientCentered Medical Home Survey assessing shared decision-making are included. The scale includes 2 items on a 4-point response scale ('not at all' to 'a lot'), and 2 'yes/no' questions. Questions include: 'In the last 12 months, did you and this provider talk about starting or stopping a prescription medicine?' and 'When you talked about starting or stopping a prescription medicine, how much did this provider talk about the reasons you might want to take a medicine?' [35] [36] [37] .
Pain treatment satisfaction
Satisfaction with pain treatment is assessed using 22 items from the 61-item Pain Treatment Satisfaction Scale developed by Evans et al. [38] . Questions are asked on fivepoint response scales and assess how much information a patient would like to receive about their treatment, questions about a patient's medical care (for example, 'The medical staff is willing to provide me with the pain medication that I feel I need'), and questions about a patient's current pain medications (for example, 'My pain medication has a positive effect on my physical health').
Patient-provider relationship
The patient-provider relationship is assessed using an adapted version of the 11-item Trust in Physician Scale developed by Thom et al. [39] , where the term 'provider' is substituted for 'doctor'. This allows the scale to be used with nurse practitioners and physician assistants. Questions are asked on a five-point response scale ('totally agree' to 'totally disagree'). Questions include: 'I trust my provider to put my medical needs above all other considerations when treating my medical problems' and 'My provider is well qualified to manage (diagnose and treat or make appropriate referral) medical problems like mine'.
General health-related quality of life (HRQL)
General HRQL is assessed using the 10-item PROMIS global health scale v.1.0/1.1 [40] . The scale includes 9 items on a 5-point response scale and one item on a 0 to 10 numerical scale. Questions include: 'In general, how would you rate your physical health?' and 'How would you rate your pain on average?'
Demographics
Demographic data will be gathered on age, gender, marital status, race, ethnicity, employment and educational attainment. All demographic questions will be asked at baseline; marital status will be also re-assessed at 26 weeks, and employment status will be assessed at 13-, 26-and 52 weeks.
Smartphone usage
Smartphone usage will be assessed at baseline using a six-item scale to determine familiarity and frequency with smartphones and apps. Questions include: 'How long have you been using a smartphone?' (less than 6 months; between 6 months and 1 year; more than 1 year), and 'Do you have any health-related Apps on your smartphone?' (yes, no). Two questions are adapted from the smartphone and medical related app use questionnaire created by Payne [41] .
Patient and clinician relationship length
Patient and clinician relationship length is assessed using 2 questions (items 3 and 4) from the 34-item CAHPS 12-month Clinician & Group Visit Survey. The questions assess how long the patient has been going to the provider and the number of visits to the provider in the last 12 months [42] . (post-trial). The purpose of this questionnaire is to evaluate intervention patient expectations and experiences with treatment and the extent to which patient expectations were met. Questions are asked on a five-point response scale.
Measures for intervention patients only
Trialist acceptability and satisfaction questionnaire
Intervention patients also complete the Trialist Acceptability and Satisfaction Questionnaire to provide feedback on the use of the Trialist app. The survey is sent to participants after the n-of-1 trial is completed. Questions contained in the survey are based upon adaptations of the System Usability Scale [43] , and the Program Acceptability and Satisfaction Survey [44] . Questions are asked on five-point response scales ('strongly disagree' to 'strongly agree') and ('not at all helpful' to 'extremely helpful'). Questions include: 'I thought the Trialist app was easy to use', 'I found the Trialist app very awkward to use' ,a n d'How satisfied were you with the reminders you received to complete your questionnaires?' 
Sample size
T h es a m p l es i z er e q u i r e df o rt h ep r o p o s e dR C Ti s b as e do nt h ep r i m ar yo u t c o m e :c h a n g ef r o mb as e l i n et o 26 weeks on the PROMIS pain interference scale. Assuming that the minimally important difference is 0.4 SD difference (4 points) and that 10% of those who enter the study will not complete an endpoint and will therefore be assigned a change of 0, the full sample (endpoint completers plus non-completers) would need to show a 3.6-point difference in order for the completers to show a minimally important difference. Assuming a common standard deviation of 10 points, each group (Trialist app and usual care) would need to include 122 patients (244 in total) in order to have 80% power to detect a 3.6-point difference in means using a 2-group t-test with a 0.05 2-sided significance level. Approximately 50 to 60 clinicians will be enrolled with each clinician being asked to enroll four to eight patients each. This reduces the burden required on any one clinician by ensuring that the maximum number of intervention patients for each clinician is two to four.
Analytical plan
The primary analysis will be intent-to-treat which uses all participants as randomized. Outcomes will be analyzed both as changes from baseline to a single time point and as longitudinal evolutions in time. Changes at a single point (for example, from baseline to 26 weeks) between the groups will be compared by a t-test for continuous outcomes and chi-square test for binary outcomes. Longitudinal outcomes will use mixed models with a fixed effect of treatment and a random effect of time and a random time by treatment interaction using the appropriate generalized linear model link function and distribution (normal for continuous outcomes; binomial for binary ones; Poisson for counts). Additional exploratory analyses will examine: potential interactions of treatment with covariates such as age, gender, type of intervention, dosage, time on treatment, physician and clinic. When no endpoint is available (for example, no pain measurements available at the 6-month time interval to calculate the outcome of change from baseline), we will use different approaches. In one, we will assume that no change has occurred and impute a change of zero. This will permit simple conservative assessments of single time point analyses. Longitudinal models can accommodate missing outcomes by ignoring them under the assumption that data are missing at random. We will also use multiple imputation to permit comprehensive analyses with missing covariates and interactions.
Analysis of N-of-1 trial results within the trialist (intervention group only)
As noted earlier, patients assigned to the Trialist are prompted to enter data on a daily basis. At the end of each person's n-of-1 trial, statistical analysis is performed in order to compare results on the two treatments. Each n-of-1 trial requires a separate analysis and the analysis is automated to run in the background once each n-of-1 trial is completed. The analysis consists of running different Bayesian models that make different assumptions about the nature of the data (for example, data with and without correlation over time, with and without carryover across interventions, and so on). The results of these models are automatically compared as to which best fits the data, and the simplest model that accurately fits the data is chosen. The goal of the model checking is to assure that the model that can provide the most accurate and precise treatment effect is chosen. Automated model choice is checked manually by the study statisticians for all initial n-of-1 trials and then periodically thereafter to ensure that reasonable models are being selected. Robust models are preferred. Patients and clinicians are provided with an estimate of the treatment difference, represented as the estimated percentage that one treatment is superior to the other and a measure of its uncertainty (for example, 95% Bayesian confidence interval) as well as the probability that each treatment is the best for each outcome. Results are portrayed numerically and graphically (see Additional file 3.) Interpretation of results is left to the patient and clinician, but clinicians will have access to instructional materials on how to interpret the graphs generated by Trialist.
Data management and monitoring
Outcome assessments will be collected via Research Electronic Data Capture (RedCap) survey or pen-and-paper. Data will be entered into RedCap databases [45] . All data that requires manual entry (for example, from a pen-andpaper surveys) will be entered by trained staff and undergo data quality and accuracy checks. Any data patients enter in the Trialist app is encrypted and uploaded to a secure server using Transport Layer Security (TLS)/Secure Sockets Layer (SSL) protocols [46, 47] . A Safety Monitoring Committee (SMC) has been established. The SMC is an independent committee comprised of researchers and clinicians who are (with one exception) not involved in the study. SMC meetings are scheduled monthly, subject to cancellation at the discretion of the SMC chair provided there are no adverse events, no unanticipated problems, and no other issues for discussion. Unanticipated and adverse events will be reported to the SMC and to the institutional review board in accordance with University of California, Davis and Veterans Affairs Northern California Health Care System (VANCHS) procedures. The SMC will report adverse events considered related to the study directly to the National Institute of Nursing Research (NINR) program official. 22 patients who enrolled at the end of the recruitment period and were not followed beyond 6 months. c P-value: Fisher's exact test d Baseline opioid use was obtained through chart abstraction on 190 patients. Missing data at 3 months = 8; missing data at 6 months = 4; and missing data at 12 months = 7.
